Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms

PharmacoEconomics

Volumn 28, Issue 8, 2010, Pages 615-628

  Golec, Joseph ^a   Vernon, John A ^b,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

Drug cost; Pharmaceutical industry; Pricing; Research and development.

Indexed keywords

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG MANUFACTURE; EUROPE; FINANCIAL MANAGEMENT; MEDICARE; ORGANIZATIONAL DEVELOPMENT; PRIORITY JOURNAL; PROFIT; REVIEW; UNITED STATES;

BIOMEDICAL RESEARCH; COST CONTROL; COSTS AND COST ANALYSIS; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; EUROPEAN UNION; FEES, PHARMACEUTICAL; GOVERNMENT REGULATION; PHARMACEUTICAL PREPARATIONS; UNITED STATES;

EID: 77954471154     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11535580-000000000-00000     Document Type: Review

References (39)

1. Ganslandt M, Maskus KE. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union. J Health Econ 2004; 23: 1035-1057
2. Congressional Budget Office. S.3 Medicare prescription drug price negotiation drug act of 2007. 2007 Apr 16 [online]. Available from URL: http://www.cbo.gov/ftpdocs/ 80xx/doc8006/s3.pdf [Accessed 2010 Apr 8]
3. Congressional Budget Office. HR1200 American health security act of 1993. 1993 Dec 16 [online]. Available from URL: http://www.cbo.gov/ftpdocs/79xx/ doc7945/93doc08b. pdf [Accessed 2010 Apr 8]
4. California Office of the Governor. California senate bill 798 prescription drug initiative. 2006 Aug 24 [online]. Available from URL: http://gov.ca.gov/index.php?/fact-sheet/3871/ [Accessed 2010 Apr 8]
5. Vernon JA. Examining the link between price regulation and pharmaceutical R&D investment. Health Econ 2005; 14: 1-16
6. Scott Morton F. The strategic response by pharmaceutical firms to Medicaid most-favored-customer rules. RAND J Econ 1997; 28: 269-290
7. Ruback R. The effect of discretionary price control decisions on equity values. J Financial Econ 1982; 10: 83-106
8. Golec J, Hegde S, Vernon JA. Pharmaceutical R&D spending and threats of price regulation. J Financial Quant Anal 2010; 45: 239-264
9. Doukas J, Switzer L. The stock market's valuation of R&D spending and market concentration. J Econ Bus 1992; 44: 95-115
10. Chan LKC, Lakonishok J, Sougiannis T. The stock market valuation of research and development spending. J Finance 2001; 56: 2431-2456
11. Eberhart AC, Maxwell WF, Siddique A. An examination of long-term stock returns and operating performance following R&D increases. J Finance 2004; 59: 623-650
12. Toppe Shortridge R. Market valuation of successful vs nonsuccessful R&D efforts in the pharmaceutical industry. J Bus Finance Accounting 2004; 31: 1301-1325
13. Vernon JA. Drug research and price controls. Regulation 2003; 23 (4): 22-25
14. US Department of Labor, Bureau of Labor Statistics. Consumer price index [online]. Available from URL: http:// www.bls.gov/cpi/ [Accessed 2010 Apr 9]
15. European Commission. Eurostat [online]. Available from URL: http://epp.eurostat.ec.europa.eu/portal/page/portal/ eurostat/home/ [Accessed 2010 Apr 9]
16. OECD. OECD health data 2003: a comparative analysis of 30 countries. Paris: OECD Publishing, 2003
17. Ellison SF, Mullin WP. Gradual incorporation of information: pharmaceutical stocks and the evolution of President Clinton's health care reform. J Law Econ 2001; 44: 89-130
18. Tessoriero H. Torrid drug price increases pause. Wall Street J 2004 Dec 6; A3
19. Standard and Poor's. Compustat [online]. Available from URL: http://www.compustat.com/products.aspx?id=2147 486990 [Accessed 2010 Apr 9]
20. Stapleton R, Subrahmanyam M. The market model and capital asset pricing theory: a note. J Finance 1983; 38: 1637-1646
21. European Federation of Pharmaceutical Industries and Associations (EFPIA). Year in review 2001-2002. Brussels: EFPIA, 2002
22. Pharmaceutical Research and Manufacturers of America. Pharmaceutical industry profile: 2005. Washington, DC: PhRMA, 2005
23. Bayer investor relations [online]. Available from URL: http://www.investor.bayer.com/en/reports/archive/ [Accessed 2010 Apr 8]
24. US Department of Commerce, Bureau of Economic Analysis. Foreign direct investment in the US: financial and operating data for US affiliates of foreign multinational companies. Selected data by industry [online]. Available from URL: http://www.bea.gov/regional/sqpi/ [Accessed 2010 Apr 9]
25. US Department of Commerce, Bureau of Economic Analysis. Foreign direct investment in the US: financial and operating data for US affiliates of foreign multinational companies. Assets by industry and country [online]. Available from URL: http://www.bea.gov/regional/sqpi/ [Accessed 2010 Apr 9]
26. The National Science Foundation. Industrial research and development information system. Company R&D performed outside the United States by industry [online]. Available from URL: http://www.nsf.gov/statistics/iris [Accessed 2010 Apr 9]
27. European Federation of Pharmaceutical Industries and Associations (EFPIA). The pharmaceutical industry in figures. Brussels: EFPIA, 2005
28. Giaccotto C, Santerre R, Vernon JA. Drug prices and research and development investment behavior in the pharmaceutical industry. J Law Econ 2005; 48: 195-214
29. Greene WH. Econometric analysis. New York: Macmillan Publishing, 1990
30. GrabowskiHG, Vernon JM.Anew look at the risks and returns to pharmaceutical R&D. Manage Sci 1990; 36 (7): 804-821
31. Myers SC, Shyam-Sunder L. Measuring pharmaceutical industry risk and the cost of capital. In: Helms RM, editor. Competitive strategies in the pharmaceutical industry. Washington, DC: American Enterprise Institute Press, 1996: 208-237
32. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-185
33. DiMasi JA, Hansen RW, Grabowski HG, et al. Cost of innovation in the pharmaceutical industry. J Health Econ 1991; 10: 107-142
34. Moris F. Industrial R&D employment in the United States and in US multinational corporations. Arlington (VA): National Science Foundation, Division of Science Resources Statistics, 2004 Dec [online]. Available from URL: http://www.nsf.gov/statistics/infbrief/nsf05302/ [Accessed 2010 Apr 8]
35. US Department of Labor, Bureau of Labor Statistics. Pharmaceutical and medical manufacturing (NAICS 3254). Washington, DC: Bureau of Labor Statistics, 2004 [online]. Available from URL: http://www.bls.gov/oco/cg/ [Accessed 2010 Apr 9]
36. US Department of Labor, Bureau of Labor Statistics. Pharmaceutical and medical manufacturing (NAICS 3254). Washington, DC: Bureau of Labor Statistics, 2004 [online]. Available from URL: http://www.bls.gov/oco/cg/ [Accessed 2010 Apr 9]
37. US Securities and Exchange Commission. Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system [online]. Available from URL: http://www.sec.gov/edgar. shtml [Accessed 2010 Apr 8]
38. Santerre RE, Vernon JA. Assessing consumer gains from a drug price control policy in the United States. Southern Econ J 2006; 73: 233-245
39. Gambardella A, Orsenigo L, Pammolli F. Global competitiveness in pharmaceuticals: a European perspective [report prepared for the Directorate General Enterprise of the European Commission]. Brussels: European Commission, 2000 Nov